Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
HNRNPU Lactylation and MG-132 Controls
2026-11-21
A cervical-cancer study links HNRNPU K181 lactylation to PHGDH transcript regulation, serine metabolism and tumor growth. (R)-MG132 has a different evidentiary role: as a low-activity MG-132 enantiomer, it is relevant to proteasome-inhibition validation but does not itself establish the lactylation mechanism or explain the reported antitumor effects.
What Astragaloside IV Evidence Can Show
2026-11-20
Astragaloside IV has a documented chemical identity and natural-product context, but those facts do not by themselves establish a molecular target, anti-inflammatory mechanism, anti-aging effect, or clinical relevance. The useful interpretation is to separate identity, material behavior, biological readouts, and disease-level evidence.
How BCL-2 Disruption Shapes AML Readouts
2026-11-20
Obatoclax mesylate is described as a broad BCL-2-family inhibitor whose molecular activity can be connected to apoptosis and loss of clonogenic growth in AML models. The documented findings support a mechanism-based interpretation, but model-specific potency and xenograft activity should not be treated as proof of clinical efficacy.
How PI3K/mTOR Inhibition Changes Tumor Signals
2026-11-19
A research-focused interpretation of how SAR245409 (XL765) connects PI3K pathway inhibition with cellular signaling, tumor-model outcomes, and the limits of those measurements.
ENO1, Annexin V, and Cardiac Repair
2026-11-19
Li et al. connected postinfarction macrophage glycolysis to ENO1, lactate accumulation, KLF4 suppression, inflammation, and adverse cardiac remodeling. This editorial separates the study’s mechanistic evidence from its downstream apoptosis measurements, explaining how annexin V fluorescence reports cell-surface phosphatidylserine exposure without independently proving irreversible cell death or establishing therapeutic efficacy.
How Calcipotriol Shapes Cell-State Readouts
2026-11-18
Calcipotriol, also called Calcipotriene, connects VDR-associated transcription with distinct cellular outcomes. The documented models support a context-dependent mechanism involving keratinocyte differentiation, immune-peptide regulation, autophagy, apoptosis, and proliferation, but they do not make these readouts interchangeable or establish equivalent effects in patients or across cancers.
What Brucine Evidence Can Establish
2026-11-18
Brucine and l-Brucine can be interpreted confidently at the level of chemical identity and selected physical properties, but product documentation alone does not establish a molecular target or biological effect. The useful distinction is between what a defined natural-product alkaloid contributes to measurement interpretation and what requires independent pharmacological evidence.
What Dual mTOR Inhibition Reveals About Cancer Signaling
2026-11-17
OSI-027 is described as a selective inhibitor of both mTORC1 and mTORC2. Its reported biochemical, cellular, and xenograft findings illustrate how pathway selectivity can translate into changes in signaling, proliferation, and cell death—while also showing why preclinical activity does not establish clinical efficacy.
What Deuterium-Labeled Degarelix Shows
2026-11-17
The cited study addressed a synthetic and analytical problem: preparing deuterium-labeled degarelix acetate as a mass-distinct internal standard. Its findings support isotope incorporation, peptide identity, and chemical characterization, but they do not provide evidence about acetoacetate biology, diabetes, or the performance of an acetoacetate material.
How to Interpret Epibrassinolide Apoptosis Claims
2026-11-16
Epibrassinolide is described as a brassinosteroid associated with apoptosis in cancer-cell models. The scientifically useful interpretation is to distinguish a broad growth-inhibition observation from evidence for selective, mechanism-linked apoptotic activity.
How PI-103 Connects Targets to Readouts
2026-11-16
PI-103 is documented as a multi-target inhibitor of class I PI3Ks, mTOR, and DNA-PK. Its reported effects on AKT, GSK3β, p70S6K, S6RP, and cancer-cell proliferation are best interpreted as pathway-level observations rather than proof that one kinase alone caused every response.
What Does β-D-Glucose Reveal in Metabolism?
2026-11-15
β-D-Glucose is a metabolic input, not a direct measurement of cellular energy production. Interpreting glucose energy metabolism requires separating substrate availability, transport, glycolysis, cellular respiration, redox balance and downstream cell-state responses.
How VPS34 Links Autophagy to Iron Balance
2026-11-14
PIK-III provides a mechanistic way to interpret how VPS34-dependent phosphatidylinositol-3-phosphate production connects autophagosome formation with ferritin turnover and iron recycling. The documented evidence spans biochemical inhibition, cellular autophagy readouts, and an animal iron-accumulation phenotype, but those measurements represent different levels of biological inference.
How Timolol Links Receptor Blockade to IOP
2026-11-13
Timolol Maleate provides a useful mechanistic example of how beta1 and beta2 adrenergic receptor inhibition can connect molecular pharmacology with intraocular pressure reduction. In an experimental glaucoma model, lower pressure coincided with less retinal ganglion cell degeneration, but the documented result does not distinguish pressure-mediated protection from a direct neuroprotective action.
How Lercanidipine Links Calcium to Vascular Tone
2026-11-13
Lercanidipine is documented as a dihydropyridine calcium channel blocker whose inhibition of L-type calcium entry provides a mechanistic bridge to vascular smooth muscle relaxation. The key interpretive distinction is that channel-level inhibition, tissue-level changes in vascular tone, and blood-pressure measurements represent related but different forms of evidence.